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Abstract
There are few reports concerning the biological role and the mechan-
isms of interaction between proteinases and carbohydrates other than
those involved in clotting. It has been shown that the interplay of
enzymes and glycosaminoglycans is able to modulate the activity of
different proteases and also to affect their structures. From the large
number of proteases belonging to the well-known protease families
and also the variety of carbohydrates described as widely distributed,
only few events have been analyzed more deeply. The term “family” is
used to describe a group of proteases in which every member shows an
evolutionary relationship to at least one other protease. This relation-
ship may be evident throughout the entire sequence, or at least in that
part of the sequence responsible for catalytic activity. The majority of
proteases belong to the serine, cysteine, aspartic or metalloprotease
families. By considering the existing limited proteolysis process, in
addition to the initial idea that the proteinases participate only in
digestive processes, it is possible to conclude that the function of the
enzymes is strictly limited to the cleavage of intended substrates since
the destruction of functional proteins would result in normal tissue
damage. In addition, the location as well as the eventual regulation of
protease activity promoted by glycosaminoglycans can play an essen-
tial role in the development of several physiopathological conditions.
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Introduction
The interaction between macromolecules
as a result of their colocalization is a tradi-
tional aspect when considering in vivo con-
ditions; however, regarding in vitro analysis,
this aspect has been neglected as a technical
impossibility or even as a cause of artifact
generation. Proteinases and glycosaminogly-
cans belong to two of the four existing mac-
romolecule groups, which also include lipids
and nucleic acids. Their widespread distri-
bution, colocalization and physicochemical
properties provide the essential features that
allow their interaction and possible func-
tional linkage. Due to the structural and func-
tional complexity present in proteinases as
well as in the glycosaminoglycan families, it
is interesting to summarize some of their
characteristics. Also, some of the interac-
tions between proteases and glycosaminogly-
cans known, their respective mechanisms
and possible biological role are presented in
Table 1.
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Table 1. Some macromolecular interactions involving proteases, their inhibitors and glycosaminoglycans and
related effects.
Ligand Structural/functional effect Biological role
Proteases
Papain Heparin, heparan Structural change, protection Physicochemical
sulfate against alkaline inactivation, model
enhancement of catalytic
activity (1)
Cathepsin B Heparin, heparan Structural change, protection Tumor growth,
sulfate against alkaline inactivation, metastasis
enhancement of catalytic
activity (2)
Cathepsin K Chondroitin sulfate Increases the stability, Bone reabsorption
enhances catalytic activity (3)
Cathepsin G Heparin Reduction of protease inhibition Inflammation and
by alpha1-antichymotrypsin, pulmonary diseases
α1-PI and eglin C (4)
Neutrophil Heparin Reduction of protease inhibition Inflammation and
elastase by α1-PI (5) pulmonary diseases
Thrombin Heparin Structural change (6) Hemostatic defects
Chimase Heparin Reduction of protease Inflammation and
inhibition by natural inhibitors (7) pulmonary diseases
Inhibitors
Cystatin Heparin Imbalance of cysteine protease
activity regulation
Antithrombin Heparin Structural change, enhancement Hemostasis
of inhibitor efficiency (8,9)
Kallistatin Heparin Steric blocking (10), reduction of Inflammation and
inhibitor efficiency pulmonary diseases
Antitrypsin-1 Heparin Enhancement of inhibitor Inflammation and
binding pulmonary diseases
TIMP-3 Heparin, heparan Interaction with extracellular Tumor growth,
sulfate matrix components (11) angiogenesis,
Secretory leukocyte Heparin Enhancement of inhibitor Inflammation
protease inhibitor efficiency (12)
Mucus proteinase Heparin Enhancement of inhibitor Inflammation and
inhibitor efficiency (4) pulmonary diseases
TIMP-3: tissue inhibitor of metalloproteinase 3; α1-PI: α1-proteinase inhibitor.
Proteinases
Proteinases form a large and diverse fam-
ily of enzymes. The term family is used to
describe a group of enzymes in which each
member shows an evolutionary relationship
to at least another one, either throughout the
whole sequence or at least in the part of the
sequence responsible for catalytic activity.
Enzymes were initially considered only as
proteins acting in digestive processes; how-
ever, they have been demonstrated to be
involved in almost every aspect of the bio-
logical machinery. By introducing one water
molecule into an amide bond of a peptide,
cleavage occurs through a reaction involv-
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ing nucleophilic attack on the carbonyl car-
bon of the scissile bond, but the actual mech-
anism varies as different subtypes are de-
scribed (13). The structural features and cata-
lytic mechanisms of the proteinases form the
basis for their classification, where the cata-
lytic amino acid residues of each type deter-
mine the family to which the proteinase be-
longs. Most of the known proteases belong
to the serine, cysteine, aspartic or metallo-
protease families (see Ref. 14 for a detailed
discussion of proteinase classification and
nomenclature).
Proteinases are also classified by their
substrate specificity, which implies the rec-
ognition of peptide bonds or residues at the
amino or carboxyl terminus of the molecule
as well as side chains of the surrounding
amino acids at the bond to be cleaved. Since
these enzymes can select biologically impor-
tant substrates, they are related to different
actions on different aspects, yielding the
necessary balance between specificity and
diversity.
Limited proteolysis, in addition to the
initial concept that proteinases participate
only in digestion processes, is important to
direct the cleavage of intended substrates
and can also be up- or down-regulated. In
spite of possible physiological roles of this
regulation, the cleavage of functional pro-
teins would result in normal tissue damage.
In this respect, it is noteworthy to evaluate the
presence of factors that are able to control
the activity of proteinases. These molecules
comprise other proteins, peptides, ions, nucleic
acids, lipids, coenzymes (vitamins, oxidants,
reducing agents), and sugars (Table 1).
Glycosaminoglycans
Large numbers of proteins in animal tis-
sues occur immobilized in the extracellular
space, on the cell surface or in the extracellu-
lar matrix. Some are anchored through inter-
actions with other proteins. However, cur-
rent research increasingly implicates proteo-
glycans as scaffold structures, designed to
accommodate proteins by noncovalent bind-
ing to their glycosaminoglycan side chains.
In particular, heparan sulfate proteoglycans
are recognized as ubiquitous protein ligands.
Binding of proteins to heparan sulfate chains
may serve a variety of functional purposes,
from simple immobilization or protection
against proteolytic degradation to distinct
modulation of biological activity of unex-
pected regularity (15).
Heparan sulfate is a ubiquitous glycosami-
noglycan of animal cells (16). These classes
of compounds are heteropolysaccharides
made up of repeating units of disaccharides,
a uronic acid residue, either D-glucuronic
acid or L-iduronic acid, and D-glucosamine
with N- and 6-O-sulfates and N-acetyl sub-
stitutions (17). Heparan sulfate occurs on
the cell surface and in the extracellular ma-
trix as proteoglycans. Most of the cellular
heparan sulfate derives from the syndecan
and glypican proteoglycans. The syndecan
family is associated with the cell membranes
via transmembrane core proteins (18), and
the glypican family is anchored by glycosylyl
phosphatidylinositol-anchor core proteins
(19). Also, heparan sulfate proteoglycans
are present in basement membranes, repre-
senting the perlecan family (20).
Heparan sulfate and heparin are particu-
larly important among glycosaminoglycans
in their ability to bind a large number of
different proteins. Heparin-like glycosami-
noglycans play a complex role in the extra-
cellular matrix, regulating a wide variety of
biological processes, including hemostasis,
inflammation, angiogenesis, growth factors,
cell adhesion, and others (21). Some of these
functions are summarized in Table 1.
Regulation of enzymatic activity
Pericellular proteolytic activity is known
to be the result of interplay between different
molecules such as receptors, tissue inhibi-
tors, and activation factors. In addition, it is
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now clear that in many tissue-remodeling
processes, including embryo development,
morphogenesis, reproduction and cancer in-
vasion, different cell populations synthesize
the individual components that are involved
in matrix degradation. To complicate mat-
ters even further, there are variations in which
cell type synthesizes which of the compo-
nents. This variation occurs according to
different biological processes, so that a given
cell type has a specific role in a given bio-
logical process (22).
Heparin and heparin-like glycosaminogly-
cans have long been known as regulators of
the proteolytic activity of some very impor-
tant serine proteases (12,23,24). In the co-
agulation cascade, for instance, several types
of zymogen activation, e.g., limited proteoly-
sis of inactive precursors, occur only in the
presence of, or are significantly improved
by, interactions taking place at the cellular or
basement membrane level where heparin-
like glycosaminoglycans and proteoglycans
are present among other molecules (25).
Moreover, it has been shown that the activa-
tion of factor XI by thrombin or factor XIa is
increased in the presence of glycosaminogly-
cans (26). On the other hand, it was also
demonstrated that the inhibitory activity of
antithrombin-III (ATIII) towards thrombin
is increased in the presence of glycosami-
noglycans. Two mechanisms have been re-
ported to contribute to the potentiation of
ATIII activity: 1) colocalization of the pro-
teins in the same heparin chain (6), and 2) a
conformational change in ATIII induced upon
its binding to heparin (27).
Structural modifications induced by
heparin binding
Glycosaminoglycans have long been
known to bind to either peptides or protein
domains that exhibit certain preferred con-
formations (28), or to induce conformational
changes upon their binding to peptides or
proteins (27). This behavior may be related
to the ability of glycosaminoglycans to act as
modulators for some proteins by changing
their catalytic activity (29), by protecting the
enzyme against alkaline pH-induced inacti-
vation (2) or by permitting some binding to
occur, by exposing binding regions on the
target protein (9).
Heparin, a highly sulfated glycosami-
noglycan present in mast cells and impli-
cated in physiopathological processes such
as cell proliferation and differentiation and
in coagulation inhibition, has been exten-
sively studied as a model of the effect of
glycosaminoglycans on protein and peptide
structure (30) as well as a modulator of
enzymatic activity (6). Heparin has the high-
est negative charge density of any known
mammalian macromolecule.
Cardin and Weintraub (31) identified two
clusters of positive charges in known hepa-
rin-binding proteins in which amino acids
tend to be arranged in the XBBXBX or
XBBBXXBX patterns, where B stands for an
amino acid with basic charge, usually argi-
nine or lysine, and X represents an uncharged
or hydrophobic amino acid. Molecular mod-
eling of these consensus sites predicts the
arrangements of these amino acids into ei-
ther α-helices or ß-strands. This permits the
clustering of non-contiguous basic amino
acids on one side of the helix domain, thus
forming a charged domain to which gly-
cosaminoglycans could bind, as observed
for some of the proteases and inhibitors listed
in Table 1.
Glycosaminoglycan participation in
extracellular matrix degradation:
proteinases and protein inhibitor
interactions
Serine protease interactions
Human polymorphonuclear leukocytes
contain a number of proteolytic enzymes
including neutrophil elastase (NE), a 30-
kDa glycoprotein that belongs to the class of
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serine proteinases. NE cleaves extracellular
matrix proteins including elastin, interstitial
collagen, fibronectin, proteoglycan and lam-
inin, as well as plasma proteins such as
antithrombin, fibrinogen, and components
of the immune system. The concentration of
NE in the azurophilic granules is thought to
be in the millimolar range. Uncontrolled re-
lease of this potent enzyme may lead to
degenerative connective tissue diseases such
as lung emphysema and rheumatoid arthritis
(32). The proteinase inhibitors responsible
for the control of NE activity are α1-protein-
ase inhibitor (α1-PI), α2-macroglobulin, and
mucus proteinase inhibitor. In vivo, the inhi-
bition of NE by mucus proteinase inhibitor
and α1-PI may be affected by compounds
present at the site where the inhibition reac-
tion takes place, with oxidants released by
polymorphonuclear neutrophils present at
sites of inflammation reducing the capacity
of NE inhibition by α1-antitrypsin (33) and
α1-PI (34). On the other hand, when heparin
is administered to some patients, it will bind
NE and decrease its rate of inhibition by α1-
PI (5). Negatively charged molecules such
as DNA released from short-lived cells such
as neutrophils are also able to affect the
enzymatic activity of NE (35).
Other serine proteases, playing major
roles in other physiological processes, have
also their proteolytic activity or inhibition
changed by heparin. Human tissue kallikrein
(hK1), for example, the enzyme responsible
for the release of kallidin (Lys-bradykinin)
from kininogen, does not have its proteolytic
activity altered by heparin. On the other
hand, kallistatin, the specific kallikrein in-
hibitor of the serpin family, has its inhibitory
activity towards hK1 deeply reduced by hep-
arin, whose binding to this serpin is different
from its binding to ATIII (another serpin)
(10,36).
Matrix metalloprotease interactions
The tissue inhibitors of metalloprotein-
ases (TIMP) are specific protein inhibitors
of the matrix metalloproteinases (MMP), a
group of zinc-dependent enzymes that in-
clude collagenases, gelatinases, and strome-
lysins. Four human forms have been cloned:
TIMP-1 (37), TIMP-2 (38), TIMP-3 (39),
and, more recently, TIMP-4 (40). TIMP-1
and TIMP-2 are secreted by many cell types
in culture and are found in body fluids and
tissue extracts. TIMP-3 is unique in that it
appears to be a component of the extracellu-
lar matrix (11) and occurs in relatively small
amounts, possibly being expressed during
specific cellular events (41). Of the four
known TIMP, TIMP-3 is distinguished by its
tighter binding to the extracellular matrix.
Glycosaminoglycans such as heparin, hepa-
ran sulfate, chondroitin-4/6-sulfate, derma-
tan sulfate and sulfated compounds such as
suramin and pentosan efficiently extract
TIMP-3 from the postpartum rat uterus. En-
zymatic treatment by heparinase III or chon-
droitinase ABC also releases TIMP-3, but
neither one alone produces complete release.
Confocal microscopy shows colocalization
of heparan sulfate and TIMP-3 in the endo-
metrium subjacent to the lumen of the uterus.
TIMP-3 binding may be important for the
cellular regulation of MMP activity (42).
The interaction of heparin with gelati-
nase A is mediated by ionic interactions,
being disrupted by 0.5 M NaCl. In the inter-
action with matrilysin, heparin increased two-
fold the rate of interaction of this protease
with TIMP-3. TIMP-3 does not contain any
of the reported linear heparin-binding mo-
tifs, but a motif defined by the three-dimen-
sional structure could exist (43). It is likely
that TIMP-3 interacts with cell surface and
extracellular matrix glycosaminoglycans via
the large number of positively charged resi-
dues in TIMP-3, and that this is the basis for
its location in the extracellular matrix both in
vivo and in cell culture. Hence, colocaliza-
tion of TIMP-3 with proenzymes in the peri-
cellular environment may be a mechanism
for increasing the rate of MMP inhibition
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and regulating extracellular matrix break-
down during morphogenetic processes.
Colocalization of TIMP-3 in the pericel-
lular environment via binding to the extra-
cellular matrix, including heparan sulfate
proteoglycans, would place this inhibitor in
a key position to inhibit MMP produced by
endothelial cells, thus regulating degrada-
tion of the extracellular matrix and release of
the angiogenic factors required for migra-
tion and angiogenesis.
Cysteine protease interactions
The effect of glycosaminoglycans on the
activity of different proteinases from the
cysteine proteinases family, namely papain
(1), cathepsin K (3), and cathepsin B (2), has
been described. In mammals, lysosomal cys-
teine proteinases have been implicated in
diseases involving tissue remodeling states,
such as inflammation (23) and tumor metas-
tasis (44). Nevertheless, the activity of ca-
thepsin D, another lysosomal cathepsin, but
pertaining to the aspartyl proteinase family,
that is overexpressed in breast tumors, to-
wards small synthetic peptides is not regu-
lated by heparin (45). The participation of
cysteine proteases in parasite infection has
also been observed (46).
Papain was the first cysteine protease
reported to interact with glycosaminogly-
cans (1). This interaction was proposed as a
model for mammalian cysteine proteinase-
glycosaminoglycan interaction and regula-
tion of the function of this class of protein-
ases in vivo. It was observed in this study that
papain exhibited high-affinity binding to
heparin, being eluted at 1.0 M NaCl from a
heparin-Sepharose column. This interaction
was specific, since this binding was dis-
rupted by the previous addition of 100 µM
free heparin to the papain solution. These
data show that papain binding to heparin is
mediated mainly by electrostatic interactions.
The presence of heparin significantly changes
the papain structure by increasing the α-
helix content of the enzyme, and the binding
event can be monitored by circular dichro-
ism analysis. This binding results in a pow-
erful increase in the affinity of the enzyme
for the substrate. It was also shown that the
interaction between heparin or heparan sul-
fate with papain is specific, since other sul-
fated glycosaminoglycans, namely derma-
tan sulfate and chondroitin sulfate, were not
able to increase the affinity of papain for the
substrate, nor did they change the α-helix
content in papain.
The observation of the interaction be-
tween a cysteine proteinase and glycosami-
noglycans was later extended to another ly-
sosomal cysteine proteinase, cathepsin K. It
is currently known that cathepsin K is the
predominant cysteine proteinase in osteo-
clast-mediated bone remodeling, and the pro-
teinase is thought to be involved in the patho-
genesis of diseases with excessive bone and
cartilage resorption (3). Chondroitin-4-sul-
fate was shown to increase cathepsin K sta-
bility in a specific and selective manner. In
kinetic terms, as a combined effect on ca-
thepsin K activity and stability parameters, a
200-fold increase was observed associated
with the presence of chondroitin-4-sulfate.
The observed increase of activity involved
the cleavage of soluble as well as insoluble
type I and II collagens.
Recently, cathepsin B, that also belongs
to the papain superfamily, was also demon-
strated to be affected by the presence of
glycosaminoglycans (2). The main feature
that distinguishes cathepsin B from other
cysteine proteinases is the presence of a
large insertion loop structure termed occlud-
ing loop, which covers the active site. It has
been shown that lysosomal cysteine protein-
ases, especially cathepsin B, can participate
in tumor invasion by degrading extracellular
matrix components (44). This can take place
either intracellularly, by heterophagosomal
activity of the tumor cell, or extracellularly
(47) by cell surface-associated cathepsin B
(48). It has been demonstrated that the pres-
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ence of cathepsin B on the plasma mem-
brane results in focal dissolution of extracel-
lular matrix proteins and enables the tumor
cell to invade (49). Trafficking and targeting
of lysosomal enzymes are mostly mediated
by mannose-6-phosphate receptor pathways
(50). However, several reports show that this
class of receptors is not sufficient for target-
ing of lysosomal enzymes along intracellular
routes, either by an alteration in these recep-
tors (51) or by changes in glycosylation pat-
tern of lysosomal enzymes, as observed for
cathepsin B in carcinoma cells (52). Indeed,
mannose-6-phosphate-independent targeting
has been proposed for cathepsin B in normal
cells (53) and in a human colon carcinoma
cell line (54). High levels of cathepsin B and
qualitative changes in cathepsin B protein
expression, including an abnormal pattern of
glycosylation, may be important in main-
taining the malignant phenotype in carcino-
ma cells. Alterations in cathepsin B expres-
sion, processing and cellular localization have
been observed in several human tumor tis-
sues, and clinical investigations have shown
that cathepsin B is a highly predictive indica-
tor for prognosis and diagnosis in cancer
(55).
As mentioned above, the presence of
cathepsin B on the plasma membrane results
in focal dissolution of extracellular matrix
proteins and enables the tumor cell to invade
the tissue. Recent results suggest that the cell
surface heparan sulfate can anchor the mem-
brane forms of cathepsin B, and such com-
plexation affects the cathepsin B activities.
The coupling of cathepsin B to heparan sul-
fate on the cell surface can potentiate the
endopeptidase activity of the enzyme by in-
creasing 5-fold its half-life at physiological
pH (2). The endopeptidase activity of ca-
thepsin B is related to the degradation of
extracellular matrix proteins. These results
agree with the observation that the mem-
brane-bound forms of cathepsin B are highly
resistant to inactivation at neutral pH. As
previously mentioned, the mechanism of se-
cretion and insertion of cathepsin B on the
plasma membrane is not fully understood.
Mannose-6-phosphate-independent targeting
has been proposed for cathepsin B. So, ac-
cording to this scenario, the cell surface
heparan sulfate proteoglycans may anchor a
pool of the membrane forms of cathepsin B.
Moreover, the cell surface heparan sulfate
proteoglycans are in a constant turnover as a
result of their continuous secretion and en-
docytosis. It has been shown that some pro-
teins bound to heparan sulfate glycosami-
noglycan chains are endocytosed together
with proteoglycans, e.g., fibroblast growth
factor, thrombospodin and lipoprotein lipases
(21). It is interesting to observe that in the
lysosomal vesicles there is a high concentra-
tion of cathepsin B and that heparan sulfate
is also present in this compartment during its
intracellular traffic. These observations sug-
gest that the mechanism of insertion of ca-
thepsin B on the plasma membrane and its
cellular traffic may depend on heparan sul-
fate proteoglycans present on the cell sur-
face.
The modulatory effect exerted by proteo-
glycans on cysteine proteinase activities is
expected to lead to new insights in the under-
standing of some molecular systems present
in pathological states, providing new targets
for drug therapy.
Discussion
Protease activity is under a fine control
since the systems susceptible to its enzy-
matic activities, such as the cascade of en-
zymes involved in the cell death response
(56), coagulation (57), and hypertension (58),
can be considered to be responsible for ho-
meostasis.
Except for digestive processes occurring
in the lumen of the intestine, proteases are
always accompanied by a specific inhibitor
with the sole function to regulate the en-
zyme’s activity. Such digestive enzymes are
also subjected to an activity control, which
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consists of the storage of the enzyme as an
inactive precursor (zymogen) and/or the
change in pH in different regions of the
intestine, leading to different enzymatic ac-
tivities being preferred. On the other hand,
tissue or plasma enzymes are normally less
concentrated than digestive enzymes and
must play their role more rapidly. This leads
to an increase in the enzyme’s specificity,
followed by the development of a more spe-
cific inhibitor responsible for assuring that
the enzyme would only play the desired role
with no further damage to the other proteins.
This fine tuning can be assured by inhibitors
alone or by other factors associated with the
enzyme control, such as glycosaminogly-
cans, which would give the system much
more flexibility in terms of action and coun-
teraction. It is noteworthy to observe, from a
structural viewpoint, the nonlinear features
of some heparin-binding sites present in
kallistatin that cannot be found among the
sites suggested for other protein inhibitors
such as TIMP-3. By comparing the two struc-
tures, the difference in the molecular mechan-
isms developed in the construction of pro-
teases belonging to different families is re-
markable. This seems to be an indication of
the multiplicity that we should take into
account when studying the interactions be-
tween carbohydrates and proteins.
Complexity seems to be the path towards
which nature has decided to evolve. Once
enzymes succeeded in lowering the activa-
tion energy required for a given reaction to
occur and speeded up the processes from an
evolutionary satisfactory point of view, regu-
lation of this catalysis probably started to
play a much more important role than the
reaction itself. Understanding the ways life
regulates itself by controlling the molecular
machinery is a necessary step to be taken as
we intend to understand life at all.
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